Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Kungalv – page 37

476 clinical trials in Kungalv, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Kungalv at a glance
476
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

476 trials in Kungalv

Open in trial search

Crohn's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Long-Term Study on Aflibercept for Retinopathy of Prematurity in Infants

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Aflibercept
  • Sponsor:Bayer AG

Study of Giredestrant, Triptorelin, and Anastrozole in Premenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:ETOP IBCSG Partners Foundation

Study on the Effect of Adding Thoracic Radiotherapy to Durvalumab and Chemotherapy for Patients with Extensive Stage Small-Cell Lung Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Study Comparing Relatlimab-Nivolumab Combination with Regorafenib or Trifluridine-Tipiracil for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Multiple sclerosis+2

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab, Methylprednisolone, and Diphenhydramine Hydrochloride in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Effectiveness and Safety of Autogene Cevumeran, Atezolizumab, and mFOLFIRINOX in Patients with Resected Pancreatic Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Sponsor:Genentech Inc.

Cardiac arrest

Not recruiting

Study on the Effects of Epinephrine, Vasopressin, and Methylprednisolone in Cardiac Arrest Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Tiohundra AB

Dermatitis atopic+1

Not recruiting

Study on the Effect of a New Moisturiser with Paraffin and Liquid Paraffin on Preventing Eczema Relapse in Children

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Glycerol
  • Sponsor:ACO Hud Nordic AB

Partial seizures

Not recruiting

Study of EQU-001 and Placebo for Patients with Uncontrolled Focal Seizures in Epilepsy

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ivermectin
  • Sponsor:Equilibre Biopharmaceuticals B.V.

Study on Selexipag and Bosentan for Children with Pulmonary Arterial Hypertension

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Bosentan
  • Sponsor:Actelion Pharmaceuticals Ltd.

Study of Nivolumab and Ipilimumab for Patients with Stage 3 Non-Small Cell Lung Cancer Not Suitable for Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol Myers Squibb International Corporation

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.